A study to evaluate the Safety, Pharmacokinetics, and Activity of Subcutaneous Cevostamab (BFCR4350A) in Patients with Relapsed or Refractory Multiple Myeloma (CAMMA 3)

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503404-89-00

Acronym

GO43227

Enrollment

Registered

2024-07-30

Start date

2021-12-08

Completion date

Unknown

Last updated

2025-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or Refractory Multiple Myeloma R/R MM

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium, Greece, Italy

None listed

Source: EU CTIS · Data processed: Feb 4, 2026